目的 观察丹参多酚酸盐联合厄贝沙坦治疗糖尿病肾病的临床疗效。方法 选取2016年3月-2017年3月在上海市浦东新区周浦医院就诊的糖尿病肾病患者76例，随机分为对照组和治疗组，每组各38例。对照组口服厄贝沙坦胶囊，150 mg/次，1次/d；治疗组在对照组的基础上静脉滴注注射用丹参多酚酸盐，100 mg/次，1次/d。两组患者均连续治疗2周。观察两组患者临床疗效，同时比较治疗前后两组患者炎性因子水平、肾功能指标和血清氧化应激指标。结果 治疗后，对照组临床效率为84.2%，显著低于治疗组的92.1%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者超敏C-反应蛋白（hs-CRP）、白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）水平显著降低（P<0.05），且治疗后治疗组hs-CRP、TNF-a和IL-6水平明显低于对照组（P<0.05）。治疗后，两组患者肌酐（Scr）、尿素氮（BUN）、24 h尿蛋白（UAR）和白蛋白肌酐比值（ACR）水平均显著降低（P<0.05），且治疗后治疗组Scr、BUN、UAR和ACR水平明显低于对照组（P<0.05）。治疗后，两组患者丙二醛（MDA）和8-羟基脱氧鸟苷（8-OHdG）水平显著降低（P<0.05），超氧化物歧化酶（SOD）和总抗氧化能力（T-AOC）水平显著升高（P<0.05），且治疗后治疗组MDA、8-OHdG、SOD和T-AOC水平明显优于对照组（P<0.05）。结论 丹参多酚酸盐联合厄贝沙坦治疗糖尿病肾病临床疗效明显，安全性高，具有一定的临床推广应用价值。

Objective To observe the curative effect of salvianolate combined with irbesartan in treatment of diabetic nephropathy. Methods Patients (76 cases) with diabetic nephropathy in Shanghai Pudong New District Zhoupu Hospital from March 2016 to March 2017 were randomly divided into control and treatment groups, and each had 38 cases. Patients in the control group were po administered with Irbesartan Capsules, 150 mg/time, once daily. Patients in the treatment group were iv administered with Salvianolate for injection on the basis of the control group, 100 mg/time, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the inflammatory factors levels, the renal function indexes, and the serum oxidative stress indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 84.2%, which was significantly lower than 92.1% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the hs-CRP, TNF-a, and IL-6 levels in two groups were significantly decreased (P<0.05), and these inflammatory factors levels in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the Scr, BUN, UAR, and ACR levels in two groups were significantly decreased (P<0.05), and the renal function indexes in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the MDA and 8-OHdG levels in two groups were significantly decreased (P<0.05), but SOD and T-AOC levels were significantly increased (P<0.05), and the serum oxidative stress indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Salvianolate combined with irbesartan has obvious clinical curative effect on diabetic nephropathy with high safety, which has a certain clinical application value.